Clinical Trials Logo

Clinical Trial Summary

In the research planned as a randomized controlled study, the experimental groups will be administered routine hyperemesis gravidarum (HG) treatment as well as chewing mint-flavored gum, while the control group will only receive routine HG treatment and no intervention will be performed. This study aims to contribute to the literature by investigating the effect of chewing mint-flavored gum on the severity of nausea and vomiting, coping with stress, and anxiety levels due to hyperemesis gravidarum in pregnant women.


Clinical Trial Description

The data of the research will be collected after the necessary institutional permission and ethics committee approval have been obtained. Women who meet the inclusion criteria for the study will be informed about the method to be followed in the research. Those who want to participate in the research will read and sign the volunteer information form. 1. Intervention Group In data collection, pregnant women will sign an informed consent form before the application. Personal Information Form, VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled out. In addition to the routine treatment plan, the application will begin at least 4 hours after the antiemetic application (Gökbulut, 2021). The application will continue by chewing mint-flavored gum twice a day for at least 15 minutes for 3 days. The VAS scale will be filled after the morning chewing application, and the VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled in after the evening application. The forms of patients discharged during this period will be filled in via phone. 2. Control Group In data collection, pregnant women will sign an informed consent form before the application. At least 4 hours after the antiemetic application (Gökbulut, 2021), the Personal Information Form, VAS Scale, PUQE Scale and Stress Coping Styles Scale and State Anxiety Scale will be filled out. Routine treatment and nursing care will be applied to the control group, and no intervention will be performed. 1. After the forms are applied, the forms will continue to be filled for 3 days: VAS Scale in the morning, VAS Scale in the evening, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale. The forms of discharged patients will be filled in via phone. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06266819
Study type Interventional
Source T.C. ORDU ÜNIVERSITESI
Contact leyla emirik
Phone +90 5062848323
Email leylayaguz@gmail.com
Status Recruiting
Phase N/A
Start date January 15, 2024
Completion date July 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT04785911 - Use of the Modified PUQE Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Completed NCT04719286 - MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy N/A
Completed NCT02300155 - Improving Multivitamin Supplementation to Pregnant Women Phase 4
Completed NCT05175079 - Acupressure in Hyperemesis Gravidarum N/A
Completed NCT05098067 - Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy Phase 2
Completed NCT01836835 - Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian N/A
Completed NCT03950167 - Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum
Completed NCT02830321 - The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women N/A
Completed NCT02541682 - Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy N/A
Terminated NCT03785691 - Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum Phase 2
Completed NCT05446025 - The Levels of the Orexin, Galanin and aMSH and CART in Patients With Hyperemesis Gravidarum
Recruiting NCT02862496 - Bone Health in Hyperemesis Gravidarum N/A
Completed NCT02163434 - Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum Phase 2
Terminated NCT05452174 - Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP) Phase 1/Phase 2
Completed NCT06245811 - Inflammation Markers in Hyperemesis Gravidarum
Completed NCT04828967 - Use of Hypnosis in Hyperemesis Gravidarum N/A
Completed NCT03127293 - Hyperemesis Gravidarum and Osteoporosis N/A
Completed NCT01559012 - Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum Phase 3
Terminated NCT00861523 - Does Thiamine Help Vomiting and Nausea in Pregnancy? Phase 3